MDMA-Assisted Therapy May Decrease PTSD Symptoms, Dissociation, Depression, and Functional Disability: A Systematic Review and Meta-Analysis
Warwick M. Green, Sanket B Raut, F. E. James, David M. Benedek, Robert J Ursano, Vincent F. Capaldi, Luke R Johnson
Harvard Review of Psychiatry September 8, 2026 DOI: 10.1097/hrp.0000000000000478 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Systematic review and meta-analysis Randomized Peer reviewed |
|---|---|
| Population | People with posttraumatic stress disorder (PTSD) |
| Measures | Clinician-Administered PTSD Scale |
| Topics | Depression MDMA PTSD |
| Key findings | MDMA-assisted psychotherapy may significantly improve PTSD symptoms, dissociation, depression, and functional impairment compared with low-dose MDMA or placebo controls combined with psychotherapy, but not sleep quality. The authors caution that evidence is limited by small samples in some trials, blinding challenges, non-standardized therapies, and a common sponsor across all trials. |
Abstract
There is a need for new effective treatment options for posttraumatic stress disorder (PTSD), as many people with PTSD do not fully recover despite current treatments. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy (MDMA-AT) is emerging as a new treatment option. We assessed the current body of MDMA-AT evidence for effectiveness in treating PTSD, associated impairments, and quality of life by conducting a systematic review and meta-analysis of randomized controlled trials. Databases from ClinicalTrials.gov, MEDLINE, PsycInfo, PsycArticles, and Cochrane Library were searched from inception to June 2025. Data from seven randomized control trials (both published and unpublished) compared MDMA-AT with low-dose MDMA or placebo control combined with psychotherapy. Identified studies were not included in recent article retractions. Effect sizes were calculated using standardized mean difference for Clinician-Administered PTSD Scale scores and mean difference for secondary measures. MDMA-AT may significantly improve PTSD, dissociation, depression, and functional impairment, compared to controls, but not sleep quality. These results support MDMA-AT for PTSD core symptoms and quality-of-life measures. The evidence, however, is limited by small sample sizes in some studies, challenges with blinding in psychedelic studies, use of non-standardized therapies, and a common sponsor for all trials. While limitations exist, these findings provide evidence for a new emerging treatment option for PTSD.
In the evidence
This study is part of the evidence base for 3 syntheses in the library. Here is how each one recorded it.
-
State of the evidence: MDMA for PTSD Supports
Across seven RCTs, MDMA-assisted psychotherapy may significantly improve PTSD symptoms, dissociation, depression, and functional impairment but not sleep quality, with limitations from small samples, blinding challenges, non-standardized therapy, and a common sponsor.
Synthesized
-
Across seven RCTs, MDMA-assisted psychotherapy may significantly improve PTSD, dissociation, depression, and functional impairment versus controls, though blinding, small samples, non-standardized therapy, and a common sponsor limit the evidence.
Synthesized
-
State of the evidence: PTSD Supports
Across seven RCTs, MDMA-assisted psychotherapy may significantly improve PTSD symptoms, dissociation, depression, and functional impairment but not sleep quality, with evidence limited by small samples, blinding challenges, and a common sponsor.
Synthesized
Comparable studies
Other systematic reviews and meta-analyses on MDMA for depression, most cited first.
Citations in the library
Cites 32
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
- The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Journal of Psychopharmacology July 19, 2010
- 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. The Lancet Psychiatry May 1, 2018
- A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD) Journal of Psychopharmacology October 31, 2012
- MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nature Medicine October 1, 2023
and 27 more in the library